Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

PURPOSE: Two phase I, single-agent studies were conducted to determine the dose and regimen of obatoclax, an antagonist of all BCL-2 antiapoptotic proteins, for evaluation in phase II trials. The two studies, GX001 and GX005, evaluated the safety and tolerability of weekly 1-hour and 3-hour infusion...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hwang, Jimmy J., Kuruvilla, John, Mendelson, David, Pishvaian, Michael J., Deeken, J.F., Siu, Lillian L., Berger, Mark S., Viallet, Jean, Marshall, John L.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703245/
https://ncbi.nlm.nih.gov/pubmed/20538761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0822
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki